Snippet: Early treatment of depression matters because prolonged symptoms can worsen mood, physical health, relationships, work performance, and overall quality of life. Treating depression promptly reduces suffering, improves recovery outcomes, and can prevent long-term emotional and physical complications.
If you’ve been struggling with depression, you’re not alone. Finding an effective treatment can often feel like a long and frustrating journey. Standard antidepressants work for many people, but they can take weeks to show any benefit—and even then, they don’t work for everyone. In fact, research suggests that if a treatment doesn’t show improvement within two weeks, the chances of full remission drop significantly. Rapid response to treatment is a key predictor of long-term success.
The Need for Faster Relief
One study found that early response to treatment within the first two weeks increases the likelihood of full remission by six times. However, with traditional antidepressants, it can take months before someone truly feels like themselves again. This delay can lead to frustration and treatment dropout. A survey of individuals with depression found that 75% were unsatisfied with their treatment, and nearly 80% felt they deserved better options. As a healthcare provider, I agree—we need better solutions beyond the traditional approach of switching from one SSRI or SNRI to another. The STAR*D trial showed that with each failed treatment attempt, success rates drop, and side effects become more prominent, leading many to discontinue treatment altogether.
The Role of Glutamate in Depression
When we think about depression treatment, we often focus on neurotransmitters like serotonin, norepinephrine, and dopamine. While these are important, growing evidence suggests that glutamate—our brain’s most abundant excitatory neurotransmitter—plays a critical role in mood, learning, memory, and overall brain health. Glutamate is also a key player in neuroplasticity, the brain’s ability to adapt and form new connections. Research indicates that disruptions in glutamate function can contribute to mood disorders and cognitive difficulties, making it an important target for treatment.
| Outcome Area | Early Treatment | Delayed or No Treatment |
|---|---|---|
| Symptom Severity | Symptoms are more likely to remain mild to moderate and respond faster to treatment | Symptoms are more likely to intensify and become harder to treat |
| Duration of Episode | Shorter depressive episodes with earlier remission | Longer episodes, often lasting months or years |
| Risk of Chronic Depression | Lower risk of depression becoming recurrent or chronic | Higher likelihood of persistent or treatment-resistant depression |
| Treatment Responsiveness | Greater response to first-line treatments (therapy and/or medication) | Reduced responsiveness, often requiring more complex treatment |
| Functional Impact | Better preservation of work, school, and social functioning | Increased impairment in daily functioning and relationships |
| Cognitive Effects | Less impact on memory, concentration, and decision-making | Greater risk of ongoing cognitive difficulties |
| Comorbid Conditions | Lower risk of developing anxiety, substance use, or sleep disorders | Higher rates of comorbid anxiety, insomnia, and substance misuse |
| Suicide Risk | Earlier intervention is associated with reduced suicide risk | Untreated depression significantly increases suicide risk |
| Overall Recovery | Higher likelihood of full remission and sustained recovery | Slower recovery and increased relapse rates |
A New Approach: Targeting Glutamate
Unlike traditional antidepressants that primarily target serotonin, a newer treatment approach focuses on glutamate. In August 2022, the FDA approved Auvelity (dextromethorphan-bupropion) for adults with major depressive disorder. This is the first and only oral antidepressant that works by modifying glutamate activity. Clinical trials showed that many patients experienced early response and remission, and long-term studies found that most continued to maintain improvements in their symptoms.
Balancing Benefits and Considerations
Like any medication, Auvelity isn’t for everyone. The most common side effects include dizziness and fatigue, which can often be managed by adjusting the timing of doses. However, it does not typically cause weight gain or sexual side effects, making it an appealing option for many patients. It’s important to have a discussion with your healthcare provider to determine if this or another treatment is the right fit for you.
Finding the Right Path Forward
Depression treatment should be personalized. While traditional antidepressants work for some, others may benefit from treatments that work faster and target different pathways in the brain. If you’ve struggled with antidepressants in the past or are looking for a solution that provides quicker relief, there are options worth exploring.
If you’re interested in learning more about innovative treatments for depression, including Auvelity, schedule a consultation to discuss your unique needs and goals. Getting better shouldn’t have to take months—we’re here to help you find the right path forward, faster.
Frequently Asked Questions: Why Fast Treatment Matters With Depression
Delaying care can allow symptoms to become more entrenched, worsen quality of life, and increase the risk of additional health or functional problems. Early treatment supports faster relief and better outcomes.
Yes. Without support, depression may become more persistent or severe, making recovery slower and more challenging.
Early intervention often leads to more rapid symptom reduction, better engagement in therapy, and improved daily functioning.
If symptoms persist for more than two weeks and interfere with daily life, seeking professional evaluation is recommended. Persistent symptoms should not be ignored.
Yes. Prolonged depression can impact interpersonal relationships, work performance, motivation, and overall functioning.
Many people feel uncertain about treatment due to stigma, fear, or misunderstanding. Talking with a trusted clinician can help clarify options and set realistic expectations.
Lifestyle habits like regular sleep, routine, light exercise, and social support can help, but they are most effective when paired with professional guidance.
Persistent lack of hope, suicidal thoughts, inability to function in daily life, or constant overwhelming sadness warrant immediate attention.
National Institute of Mental Health (NIMH)
https://www.nimh.nih.gov/health/topics/depression
Evidence on depression progression, treatment outcomes, and suicide riskWorld Health Organization (WHO)
https://www.who.int/news-room/fact-sheets/detail/depression
Global data on untreated depression, disability, and early interventionAmerican Psychiatric Association (APA)
https://www.psychiatry.org/patients-families/depression/what-is-depression
Clinical evidence on early treatment benefits and functional outcomesJournal of Affective Disorders – Duration of Untreated Depression
https://www.sciencedirect.com/science/article/pii/S0165032717312432
Peer-reviewed evidence showing longer untreated duration predicts poorer outcomesThe Lancet Psychiatry – Early Intervention Outcomes
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30077-9/fulltext
Early treatment linked to improved long-term prognosis
